17 September 2020 
EMA/487752/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Symkevi 
tezacaftor / ivacaftor 
On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Symkevi. The marketing authorisation holder for this medicinal product is Vertex Pharmaceuticals 
(Ireland) Limited. 
The CHMP recommended the approval of a new 50/75-mg strength for Symkevi tablets and an extension 
to the existing indication to allow use in children from 6 years of age. The full indication will now be as 
follows:2 
Symkevi is indicated in a combination regimen with ivacaftor 150 mg tablets for the treatment of 
patients with cystic fibrosis (CF) aged 6 12 years and older who are homozygous for the F508del 
mutation or who are heterozygous for the F508del mutation and have one of the following 
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, 
L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 
3272-26A→G, and 3849+10kbC→T. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
